Immunic to implement 1-for-10 reverse stock split

Immunic to implement 1-for-10 reverse stock split Proactive uses images sourced from Shutterstock

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27, as part of efforts to meet contractual obligations tied to a recent securities agreement.

The reverse split will take effect at 12:01 a.m. Eastern Time, with the company’s shares continuing to trade on the Nasdaq Capital Market under the ticker symbol “IMUX.” Trading on a split-adjusted basis is set to begin at market open the same day.

The decision follows approval from shareholders at a special meeting held on April 14, where investors authorized a reverse split ratio ranging from 1-for-10 to 1-for-30. The company’s board of directors subsequently selected the 1-for-10 ratio.

Under the terms of the split, every ten existing shares will be consolidated into one share. As a result, the number of outstanding shares is expected to decrease from approximately 136 million to about 13.6 million. The total number of authorized shares and the stock’s par value will remain unchanged.

No fractional shares will be issued. Instead, fractional entitlements will be aggregated and sold on the open market, with affected shareholders receiving proportional cash payments based on the proceeds.

The company stated that the reverse split will not alter shareholders’ proportional ownership, except in cases where fractional shares result in cash payments. Additionally, outstanding equity-based instruments, such as stock options, warrants, and restricted stock units, will be adjusted proportionally to reflect the new share structure.

Immunic indicated that the move is primarily intended to help fulfill obligations under a securities purchase agreement entered into with institutional and accredited investors earlier in February 2026.

View Comments